electroCore’s Truvaga™ Plus Wins Woman’s World Magazine 50 over 50 Award
electroCore (Nasdaq: ECOR) announces that its wellness product Truvaga Plus has received recognition in the first-ever Woman's World Magazine 50 over 50 Award. The award evaluation criteria included quality, effectiveness, and value, specifically targeting products beneficial for women over 50. The product is designed to help reduce stress, enhance sleep quality, and improve mental focus. CEO Dan Goldberger expressed pride in this recognition, emphasizing the company's commitment to developing solutions that enhance quality of life.
electroCore (Nasdaq: ECOR) annuncia che il suo prodotto per il benessere Truvaga Plus ha ricevuto un riconoscimento nel primo Woman's World Magazine 50 over 50 Award. I criteri di valutazione dell'award includevano qualità, efficacia e valore, con un focus particolare sui prodotti utili per le donne oltre i 50 anni. Il prodotto è progettato per aiutare a ridurre lo stress, migliorare la qualità del sonno e aumentare la concentrazione mentale. Il CEO Dan Goldberger ha espresso orgoglio per questo riconoscimento, sottolineando l'impegno dell'azienda nel sviluppare soluzioni che migliorano la qualità della vita.
electroCore (Nasdaq: ECOR) anuncia que su producto de bienestar Truvaga Plus ha sido reconocido en el primer Woman's World Magazine 50 over 50 Award. Los criterios de evaluación del premio incluían calidad, efectividad y valor, específicamente dirigidos a productos beneficiosos para mujeres mayores de 50 años. El producto está diseñado para ayudar a reducir el estrés, mejorar la calidad del sueño y aumentar la concentración mental. El CEO Dan Goldberger expresó su orgullo por este reconocimiento, enfatizando el compromiso de la empresa en desarrollar soluciones que mejoren la calidad de vida.
electroCore (Nasdaq: ECOR)는 자사의 웰빙 제품 Truvaga Plus가 최초의 Woman's World Magazine 50 over 50 Award에서 인정을 받았다고 발표했습니다. 이 상의 평가 기준에는 품질, 효과 및 가치가 포함되어 있으며, 특히 50세 이상의 여성에게 유익한 제품에 초점을 맞추고 있습니다. 이 제품은 스트레스를 줄이고, 수면의 질을 향상시키며, 정신 집중력을 개선하도록 설계되었습니다. CEO Dan Goldberger는 이 인정을 받게 되어 자랑스럽다고 표현하며, 삶의 질을 향상시키는 솔루션을 개발하는 회사의 의지를 강조했습니다.
electroCore (Nasdaq: ECOR) annonce que son produit de bien-être Truvaga Plus a été reconnu lors du tout premier Woman's World Magazine 50 over 50 Award. Les critères d'évaluation du prix incluaient la qualité, l'efficacité et la valeur, en ciblant spécifiquement les produits bénéfiques pour les femmes de plus de 50 ans. Le produit est conçu pour aider à réduire le stress, améliorer la qualité du sommeil et accroître la concentration mentale. Le PDG Dan Goldberger a exprimé sa fierté pour cette reconnaissance, soulignant l'engagement de l'entreprise à développer des solutions qui améliorent la qualité de vie.
electroCore (Nasdaq: ECOR) gibt bekannt, dass sein Wellness-Produkt Truvaga Plus im ersten Woman's World Magazine 50 over 50 Award ausgezeichnet wurde. Die Bewertungskriterien für den Preis umfassten Qualität, Effektivität und Wert, mit einem speziellen Fokus auf Produkte, die für Frauen über 50 von Vorteil sind. Das Produkt wurde entwickelt, um Stress abzubauen, die Schlafqualität zu verbessern und die mentale Konzentration zu steigern. CEO Dan Goldberger äußerte seinen Stolz über diese Anerkennung und betonte das Engagement des Unternehmens, Lösungen zu entwickeln, die die Lebensqualität verbessern.
- None.
- None.
ROCKAWAY, N.J., Nov. 20, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, is proud to announce that its flagship wellness product, Truvaga Plus, has been recognized in the inaugural Woman’s World Magazine 50 over 50 Award. Products were evaluated based on quality, effectiveness, and value, with these awards honoring outstanding products for women over 50. A link to the article can be found here: Woman’s World 50 Over 50 Awards.
“We are thrilled to receive the Woman’s World Magazine 50 over 50 Award for Truvaga Plus,” stated Dan Goldberger, CEO of electroCore. “This honor highlights our dedication to creating solutions that enhance quality of life by alleviating stress, improving sleep, and sharpening mental focus. We take great pride in Truvaga Plus being recommended by Woman’s World Magazine.”
About Woman’s World Magazine
Woman’s Magazine, published by a360media, is a beloved publication offering diverse content tailored to women’s interests. Known for its engaging and uplifting tone, the magazine covers a wide range of topics, including health, wellness, beauty, fashion, relationships, recipes, and inspirational stories. The magazine reaches a total audience of 5.2 million.
For more information, please visit https://www.womansworld.com. Such website, and the information on such website, is neither part of this press release nor incorporated by reference herein.
About Truvaga Plus
Truvaga Plus is a revolutionary handheld vagus nerve stimulator that utilizes the company’s proven technology to quickly and gently activate the vagus nerve. It’s designed to work with the body to balance the nervous system to feel calmer, think clearer, and sleep better. Truvaga Plus is intended for general health and wellness purposes only and is not intended to diagnose, cure, mitigate, treat, or prevent any disease.
For more information, please visit www.truvaga.com.
About electroCore, Inc.
electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company dedicated to improving health and promoting general wellness through its non-invasive vagus nerve stimulation (“nVNS”) technology platform. The company’s is focused on the commercialization of medical devices for the management and treatment of certain medical conditions and consumer product offerings utilizing nVNS to promote general wellbeing and human performance in the United States and select overseas markets.
For more information, visit www.electrocore.com.
Forward-Looking Statements
This press release and other written and oral statements made by representatives of electroCore may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements about electroCore's business prospects, new and existing wellness product offerings, new ecommerce site, and clinical and product development plans; its pipeline or potential markets for its technologies; the timing, outcome and impact of regulatory, clinical and commercial developments including focus group study results; the Company’s business prospects in the United States (including its e-commerce initiatives) and other new markets and other statements that are not historical in nature, particularly those that utilize terminology such as "anticipates," "will," "expects," "believes," "intends," other words of similar meaning, derivations of such words and the use of future dates. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to raise the additional funding needed to continue to pursue electroCore’s business and product development plans, the inherent uncertainties associated with developing new products or technologies, the ability to commercialize gammaCore™, the ability to successfully launch and commercialize Truvaga Plus, the potential impact and effects of COVID-19 on the business of electroCore, electroCore’s results of operations and financial performance, and any measures electroCore has and may take in response to COVID-19 and any expectations electroCore may have with respect thereto, competition in the industry in which electroCore operates and overall market conditions. Any forward-looking statements are made as of the date of this press release, and electroCore assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents electroCore files with the SEC available at www.sec.gov.
Contact:
ECOR Investor Relations
(973) 302-9253
investors@electrocore.com
FAQ
What award did electroCore's Truvaga Plus (ECOR) win in 2024?
What are the main benefits of electroCore's Truvaga Plus (ECOR)?
What criteria were used to evaluate products for the Woman's World Magazine 50 over 50 Award?
Who is the target demographic for electroCore's Truvaga Plus (ECOR)?
